UNITED LAB (03933): UBT251 injection OSA indications granted clinical trial implied license.

UNITED LAB (03933) announced that on February 2, 2026, its wholly-owned subsidiary Federal Biotechnology (Zhuhai Hengqin) Co., Ltd. (Federal Biotechnology) received the implied clinical trial approval from the China National Medical Products Administration for the Type 1 innovative drug UBT251 injection developed independently by the company, which is indicated for the treatment of moderate to severe obstructive sleep apnea (OSA) with obesity. The acceptance number is CXHL2501306. UBT251 injection is a multi-target peptide receptor agonist independently developed by Federal Biotechnology, which can reduce blood sugar and inhibit weight gain by acting on the glucagon-like peptide-1 (GLP-1) receptor, glucose-dependent insulinotropic polypeptide (GIP) receptor, and glucagon (GCG) receptor. Weight-loss drugs represented by GLP-1 are expected to meet the significant clinical needs in the treatment of OSA. In addition, the indications of UBT251 injection for overweight or obesity, type 2 diabetes, metabolic-related fatty liver disease and chronic kidney disease have already undergone Phase II clinical trials in China. As the first new drug in China targeting the three receptors of GLP-1/GIP/GCG, UBT251 will help the company to occupy an important position in the research field of this type of drug. In the future, the company will continue to focus on new product development and enhance competitiveness and creativity in the biopharmaceutical industry, expecting to create greater benefits for the company and its shareholders.